Conference Coverage

Robot-assisted abdominoperineal resection outperforms open or laparoscopic surgery for rectal cancers


 

AT ESMO 2017

– The automaton uprising continues: Robot-assisted abdominoperineal resection (APR) can be safely performed in patients with rectal cancers within 5 cm of the anal verge, with surgical results equivalent to those seen with open or laparoscopic APR, investigators say.

Robot-assisted procedures were associated with a significantly lower rate of postoperative complications and with faster functional recovery than either laparoscopic or open surgery in a randomized trial, reported Jianmin Xu, MD, PhD., from Fudan University in Shanghai, China, and colleagues in a scientific poster presented at the European Society for Medical Oncology Congress.

“Retrospective studies have showed that robotic surgery was better than laparoscopic surgery in ensuring radical resection, reducing complications, and promoting recovery. However, there is no clinical trial reported for robotic surgery for rectal cancer. Thus, we conduct this randomized controlled trial to compare the safety and efficacy of robotic, laparoscopic, and open surgery for low rectal cancer,” they wrote.

Dr. Xu and colleagues enrolled 506 patients from 18 to 75 years of age with clinical stage T1 to T3 cancers within 5 cm of the anal verge and no distant metastases and randomly assigned them to resection with either a robot-assisted, laparoscopic, or open APR technique. Three of the 506 patients randomized did not undergo resection, leaving 503 for the per-protocol analysis presented here.

For the primary endpoint of complications rates within 30 days following surgery, the investigators found that patients assigned to robotic-assisted surgery (173 patients) had a total complication rate of 10.4%, compared with 18.8% for 176 patients assigned to laparoscopy (P = .027), and 26% for 154 assigned to open APR (P less than .001). The latter group included four patients assigned to laparoscopy whose procedures were converted to open surgery.

Among patients without complications, robot-assisted procedures were also associated with faster recovery, as measured by days to first flatus, at a median of 1 vs. 2 for laparoscopy and 3 for open procedures (P less than .001 for robots vs. each other surgery type). The robotic surgery was also significantly associated with fewer days to first automatic urination (median 2 vs. 4 for each of the other procedures; P less than .001), and with fewer days to discharge (median 5 vs. 7 for the other procedures; P less than .001).

Dr. Jianmin Xu

There were no significant differences among the groups in resection margins achieved or numbers of lymph nodes harvested.

"These are excellent postoperative complication rates reported, especially for the robotic treatment group, commented Thomas Gruenberger, MD, an oncologic surgeon at Rudolf Hospital in Vienna, in a poster discussion session.

“We all are now favoring laparoscopic surgery for these kinds of patients. The robot is a nice thing to have; however, we cannot use it in every hospital because it’s still quite expensive,” he said.

“We require – and this is a secondary endpoint of the study – long-term follow-up for local and distant outcomes,” he added,

The investigators did not report a funding source. All authors declared having no conflicts of interest. Dr. Gruenberger disclosed research funding, speakers bureau participation, and/or advisory roles with several companies.

Recommended Reading

Is pain or dependency driving elevated opioid use among long-term cancer survivors?
MDedge Hematology and Oncology
Reduced starting dose of sorafenib for HCC appears safe
MDedge Hematology and Oncology
Management of high-grade pleomorphic sarcoma with colon metastasis
MDedge Hematology and Oncology
An ASCO 2017 recap: significant advances continue
MDedge Hematology and Oncology
Minimally invasive esophagectomy may mean less major morbidity
MDedge Hematology and Oncology
FDA approves biosimilar to bevacizumab
MDedge Hematology and Oncology
FDA approves nivolumab for HCC patients
MDedge Hematology and Oncology
Consider adding chemotherapy after GI surgery
MDedge Hematology and Oncology
Study shows childhood IBD increased cancer risk in adulthood
MDedge Hematology and Oncology
FDA approves pembrolizumab for gastric and GEJ adenocarcinoma
MDedge Hematology and Oncology